Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04072952 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
A Phase 1 study of Breast Cancer, sponsored by Arvinas Estrogen Receptor.
- Active
- Registry status
- Phase 1
- Development phase
- 217
- Enrollment target
- 16
- Study locations
NCT04072952: Active Phase 1 study of Breast Cancer, sponsored by Arvinas Estrogen Receptor.
NCT04072952 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Arvinas Estrogen Receptor. The registered enrollment target is 217 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04072952, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Arvinas Estrogen Receptor.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 217 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.
Primary Outcome
First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug
Conditions Studied
Interventions
- DRUG ARV-471
- DRUG ARV-471 in combination with palbociclib (IBRANCE®)
Study Locations (16)
California
- Clinical Trial Site - Palo Alto
- Clinical Trial Site - San Francisco
- Clinical Trial Site - Santa Monica
Florida
- Clinical Trial Site - Fort Myers
- Clinical Trial Site - Tampa
Massachusetts
- Clinical Trial Site - Boston
- Clinical Trial Site - Boston
Connecticut
- Clinical Trial Site - Norwalk
Illinois
- Clinical Trial Site - Chicago
Michigan
- Clinical Trial Site - Ann Arbor
Missouri
- Clinical Trial Site - St Louis
New Jersey
- Clinical Trial Site - East Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2026-02-27 |
| Phase | Phase 1 |
What the registry record for NCT04072952 still lists
NCT04072952 is an interventional study that assigns participants to a tested intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which ARV-471 is the first listed.
NCT04072952 lists 16 locations in 12 states (California, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04072952 about?
NCT04072952 is a clinical study titled "A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer". This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) lo...
What is the current status of trial NCT04072952?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 217 participants. The study started on 2019-08-05. Estimated completion is 2026-02-27.
What conditions does trial NCT04072952 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04072952?
The interventions under investigation include: ARV-471 (DRUG), ARV-471 in combination with palbociclib (IBRANCE®) (DRUG).
Who is sponsoring clinical trial NCT04072952?
This trial is sponsored by Arvinas Estrogen Receptor, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04072952 being conducted?
This trial has 16 study locations across California, Connecticut, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04072952's enrollment target sits among peer trials
217 346th of 1224 higher than 878 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI